Brought to you by 
After second attempt, Argos Therapeutics finalizes $46.3mm IPO on Nasdaq
26 Feb 2015
Executive Summary
Cancer and infectious disease immunotherapy company Argos Therapeutics Inc. netted $46.3mm through an IPO of 6.2mm shares (including partial exercise of the overallotment) at $8, selling more shares than the 4.25mm it originally expected, when it filed in December 2013, but below its proposed $13-15 range. In Argos’ first attempt to go public in July 2011, it set terms at 5.25mm shares with a $13-15 price range, but withdrew the offering in March 2012 due to poor market conditions.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
After second attempt, Argos Therapeutics finalizes $46.3mm IPO on Nasdaq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice